Catheter ablation for ventricular tachycardia in structural heart disease currently yields unsatisfactory outcomes, prompting the need for newer mapping technologies to address multifactorial limitations.
This review highlights the limitations of current mapping approaches for ventricular tachycardia ablation in structural heart disease and explores emerging technologies to improve outcomes.
Recurrent episodes of ventricular tachycardia in patients with structural heart disease are associated with increased mortality and morbidity, despite the life-saving benefits of implantable cardiac defibrillators. Reducing implantable cardiac defibrillator therapies is important, as recurrent shocks can cause increased myocardial damage and stunning, despite the conversion of ventricular tachycardia/ventricular fibrillation. Catheter ablation has emerged as a potential therapeutic option either for primary or secondary prevention of these arrhythmias, particularly in post-myocardial infarction cases where the substrate is well defined. However, the outcomes of catheter ablation of ventricular tachycardia in structural heart disease remain unsatisfactory in comparison with other electrophysiological procedures. The disappointing efficacy of ventricular tachycardia ablation in structural heart disease is multifactorial. In this review, we discuss the issues surrounding this and examine the limitations of current mapping approaches, as well as newer technologies that might help address them.
Graham et al. (Sun,) conducted a review in Ventricular tachycardia in structural heart disease. Catheter ablation and mapping technologies was evaluated. Catheter ablation for ventricular tachycardia in structural heart disease currently yields unsatisfactory outcomes, prompting the need for newer mapping technologies to address multifactorial limitations.